ElevateBio
- Company typePrivate
- Founded2017
- HeadquartersWaltham, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
ElevateBio firmographics
Firmographics- Name
- ElevateBio
- Legal name
- ElevateBio
- Website
- https://elevate.bio
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
ElevateBio industry classification
Industry- Product category
- Cell and Gene Therapy CDMO
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Cell Therapy CDMO (HLAGABAD), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where ElevateBio is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
ElevateBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Infrastructure, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- CDMO Manufacturing Services: Contract development and manufacturing services for cell therapies, viral vectors (lentiviral and AAV), and mRNA. Services span from preclinical through commercial cGMP manufacturing, with dedicated manufacturing suites and integrated process development, analytical, and regulatory support.
- Gene Editing Discovery Services: Partner access to proprietary gene editing technologies and discovery-stage expertise, including proof-of-concept studies, candidate engineering, and clinical lead optimization services.
- Technology Licensing: Licensing of proprietary technologies including iPSC lines, gene editing tools, and delivery platforms to biopharmaceutical partners for their therapeutic programs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
ElevateBio product offering
Product offeringCore offering
ElevateBio is a technology-driven advanced therapy Contract Development and Manufacturing Organization (CDMO) that partners with biopharmaceutical companies to develop and manufacture cell and gene therapies. The company operates an integrated platform spanning proprietary gene editing technologies across five editing modalities, AI-powered protein discovery, and cGMP manufacturing capabilities for cell therapies, viral vectors, and mRNA. Services cover the full development journey from early discovery and process development through clinical supply and commercial manufacturing.
Product overview
ElevateBio is a technology-driven advanced therapy CDMO offering an integrated platform spanning gene editing technologies, discovery services, and cGMP manufacturing capabilities. The core offering consists of Gene Editing Design & Optimization Services (covering five editing modalities: nuclease editing, base editing, RT editing, epigenetic editing, and targeted gene insertion) paired with manufacturing services (cGMP Manufacturing, Process Development, Analytical Development, Next-Generation Sequencing, Quality, and Regulatory CMC). The technology portfolio includes proprietary platforms: the Gene Editing Technology Platform, LentiPeak Lentiviral Vector Platform, AAV Platform, LNP Delivery Platform, mRNA Platform, and iPSC Platform. A Generative AI Platform enables AI-powered protein discovery and optimization. The company operates two BaseCamp manufacturing facilities in Waltham, MA and Pittsburgh, PA, providing end-to-end services from discovery through commercialization for cell therapies, viral vectors, and mRNA.
Differentiator
Problem solved
Functional benefit
Brands
- Life Edit: Gene editing platform providing CRISPR systems and novel editing technologies including nucleases, base editors, and epigenetic editors for flexible genome access
- HighPassBio
- BaseCamp
- LentiPeak
Products and services
- Gene Editing Design & Optimization Services Comprehensive gene editing services spanning five editing modalities including nuclease editing, base editing, reverse transcriptase editing, epigenetic editing, and targeted gene insertion for both ex vivo and in vivo therapeutic applications; serves biopharmaceutical developers of cell and gene therapies.
- cGMP Manufacturing Services Clinical and commercial cGMP manufacturing across three modalities: cell therapies (autologous and allogeneic), viral vectors (lentiviral and AAV), and mRNA; provided at purpose-built BaseCamp facilities for biopharmaceutical partners.
- Process Development Services Cell and gene therapy process development spanning optimization, scale-up, process characterization, and process validation with platform processes for cell therapy and viral vector manufacturing; serves advanced therapy developers.
- Analytical Development Services Customized analytical assay development for cell therapies and viral vectors including assay development, stability testing, and platform assays for product safety, potency, purity, and identity; serves biopharmaceutical partners.
- Next-Generation Sequencing Services Comprehensive NGS services including amplicon, whole exome, whole genome, RNA (including single-cell), methyl, and complete plasmid sequencing with integrated bioinformatics analysis; serves gene therapy and cell therapy developers.
- Quality Services Quality assurance and validation, product QC release testing with 40+ in-house state-of-the-art quality control release methods, supporting in-process control and cGMP product release for advanced therapy developers.
- Regulatory CMC Services Regulatory affairs support across preclinical, clinical, and commercial stages including regulatory filing preparation, Module 3 Quality sections, and health authority interactions; serves biopharmaceutical and biotech clients.
Quantifiable outcome
- 98% manufacturing batch success rate in 2025
- +4 more outcomes
Companies that use ElevateBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
ElevateBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature8 records
ElevateBio partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, minor and core.
- SartoriusmajorPilot partnership for Eveo Cell Therapy Platform - an integrated automated system for autologous cell therapy manufacturing. Demonstrated nearly fourfold capacity increase and ~90% cost reduction. ElevateBio as preferred early-access partner with orders starting September 2026.
- PathmakerBio ConsortiumminorPartnership with Northeastern University, Bridgewater State University, and BioConnects New England to launch biomanufacturing training program (PathmakerBio) providing hands-on training in protein and cell/gene therapy manufacturing for underserved communities.
- Kyverna TherapeuticsmajorManufacturing partnership for Kyverna's Ingenui-T cell therapy, advancing cell therapy programs for autoimmune diseases using ElevateBio's manufacturing expertise.
- Novo NordiskcoreMulti-target R&D collaboration worth up to ~$1.9 billion to discover and develop gene editing therapies for rare and cardiometabolic diseases. Leverages ElevateBio's Life Edit gene editing technologies and manufacturing capabilities.
- Amazon Web Services (AWS)coreMulti-year collaboration leveraging generative AI and cloud computing to expand and accelerate CRISPR discovery, design, and drug development for complex monogenic and polygenic diseases. Uses protein language models trained on ElevateBio's proprietary protein databases.
- ModernacoreStrategic collaboration to accelerate development of novel in vivo gene editing therapies. Combines Moderna's mRNA expertise with ElevateBio's Life Edit gene editing technologies and delivery platforms.
- Affini-T TherapeuticsmajorPartnership to advance Affini-T's T cell therapy programs targeting core oncogenic drivers, leveraging ElevateBio's manufacturing and gene editing capabilities.
- University of Pittsburghcore30-year strategic partnership to establish Pitt BioForge Biomanufacturing Center at Hazelwood Green in Pittsburgh. ElevateBio to operate manufacturing facilities within the facility for cell and gene therapy development, backed by $100M grant from Richard King Mellon Foundation.
- California Institute for Regenerative Medicine (CIRM)majorPartnership to accelerate development of regenerative medicines, providing manufacturing support for cell and gene therapy programs advancing through clinical development.
- George Daley / Boston Children's HospitalmajorFormation of new company with George Daley (Harvard Medical School) and Boston Children's Hospital to develop iPSC-derived allogeneic immune therapies, combining academic research with ElevateBio's manufacturing platform.
- Boston Children's HospitalmajorFive-year cell and gene therapy collaboration to advance development of novel therapies. Combines clinical insights with ElevateBio's manufacturing capabilities.
- Massachusetts General Hospitalmajor10-year alliance agreement for ElevateBio BaseCamp to manufacture innovative cell and gene therapies developed by MGH researchers and clinicians.
- Beam TherapeuticsmajorManufacturing collaboration for base editing therapies where ElevateBio helped establish the manufacturing blueprint for a novel class of gene-edited therapy.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
ElevateBio competitors and assessment
Company assessmentDirect peers
- Genezen: Viral vector and gene therapy CDMO offering process development, analytical, and cGMP manufacturing services for gene therapy developers. Comparable to ElevateBio's lentiviral and AAV vector CDMO business.
- National Resilience: Technology-focused biomanufacturing company with cell and gene therapy manufacturing capabilities serving biotech and pharma clients. Comparable to ElevateBio as a purpose-built advanced therapy manufacturing partner.
- SK Pharmteco (Yposkesi): Cell and gene therapy CDMO specializing in viral vector and cell therapy manufacturing, formed through Yposkesi's acquisition and integration. Comparable to ElevateBio's viral vector and cell therapy CDMO focus.
- Lonza: Global CDMO leader with a substantial cell and gene therapy manufacturing franchise offering viral vector, cell therapy, and integrated process development services. Directly comparable to ElevateBio across lentiviral/AAV vector manufacturing and autologous/allogeneic cell therapy capabilities.
- Catalent (Novo Holdings): Major cell and gene therapy CDMO with viral vector and cell therapy manufacturing services across multiple global sites. Closely comparable to ElevateBio's BaseCamp model for clinical and commercial cGMP production of advanced therapies.
- Oxford BioMedica: Specialist lentiviral vector CDMO providing process development and GMP manufacturing services for cell and gene therapy developers. Highly comparable to ElevateBio's LentiPeak platform and lentiviral vector CDMO offering.
- Charles River Laboratories: CDMO with growing cell and gene therapy manufacturing capabilities alongside broader biologics and viral vector services. Comparable to ElevateBio as a multi-modality CDMO partner (and notably a fellow member of the Akadeum CDMO Alliance with ElevateBio).
- AGC Biologics: CDMO offering cell therapy, viral vector, and gene therapy manufacturing services globally. Comparable to ElevateBio's integrated CDMO model for advanced therapy developers.
- WuXi Advanced Therapies: Cell and gene therapy CDMO offering viral vector, cell therapy, and plasmid manufacturing services. Directly comparable to ElevateBio's advanced therapy CDMO capabilities across modalities.
Broad incumbents
- Thermo Fisher Scientific (Patheon): Diversified life sciences CDMO and tools provider whose pharma services segment includes cell and gene therapy manufacturing. Overlaps with ElevateBio's CDMO offering but as part of a much broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ElevateBio social profiles
Digital presenceElevateBio compliance and trust
Trust signalCompliance3 records
ElevateBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ElevateBio leadership team
Management profileNumber of profiles
Profiles17 records
ElevateBio subsidiaries and ownership
Company hierarchySubsidiaries3 records
ElevateBio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ElevateBio M&A and investment
M&A and investmentM&A1 record
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ElevateBio
What does ElevateBio do?
ElevateBio is a technology-driven advanced therapy Contract Development and Manufacturing Organization (CDMO) that partners with biopharmaceutical companies to develop and manufacture cell and gene therapies. The company operates an integrated platform spanning proprietary gene editing technologies across five editing modalities, AI-powered protein discovery, and cGMP manufacturing capabilities for cell therapies, viral vectors, and mRNA. Services cover the full development journey from early discovery and process development through clinical supply and commercial manufacturing.
Is ElevateBio a public or private company?
ElevateBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was ElevateBio founded?
ElevateBio was founded in 2017. It employs 251 to 500 people.
Where is ElevateBio based?
ElevateBio is headquartered in Waltham, United States, in the North America region.
How does ElevateBio make money?
Three revenue lines are on record. CDMO Manufacturing Services are the primary driver. The others are gene Editing Discovery Services and technology Licensing.
Who are ElevateBio's main competitors?
Direct peers on record are Genezen, National Resilience, SK Pharmteco (Yposkesi), Lonza, Catalent (Novo Holdings), Oxford BioMedica, Charles River Laboratories, AGC Biologics and WuXi Advanced Therapies. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent.
Does ElevateBio have an API?
No public API is recorded for ElevateBio.
What industry is ElevateBio in?
ElevateBio's product category is Cell and Gene Therapy CDMO. Its primary akta.pro industry code is HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325412 and its SIC code is 2834.